MarketVIEW: Herpes Simplex Virus vaccines (therapeutic)

• Publication date: July 2012
• Report size: 66 pages

Herpes Simplex Virus (HSV) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging. Vaccine manuf...

Herpes Simplex Virus (HSV) is a sexually transmitted virus which is a major cause of genital herpes (GH). Although most individuals infected with HSV-2 have minimal signs of infection, the disease is life-long and in some, causes considerable emotional and physical distress. Individuals asymptomatically infected with HSV-2 can continue to transmit virus making its containment at the public health level extremely challenging.

Vaccine manufacturers have pursued the development of both prophylatic (PX) and therapeutic (TX) HSV vaccines albeit with little success to date. For therapeutic approaches a vaccine could reduce the frequency/duration of recurrences and lessen the need for long-term pharmacotherapy. Ideally the vaccine would also reduce transmission so having a wider public health benefit. 

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative THERAPEUTIC (TX) HSV vaccine until 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI target product profile (TPP) scenarios are included which examine the uptake of vaccines with differing clinical performance. A detailed review is also included on latest trends in disease epidemiology/dynamics.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL 

Drug And Medication Industry in Europe

Contents – Summary presentation (MS PowerPoint based)
Author’s note
Executive Summary
Point(s) to note regarding vaccine pricing/usage
Commercial model – key model outputs
HSV TX vaccine: available market ($000s) to 2030 by scenario
HSV TX vaccine: demand (000s doses) to 2030 by scenario
HSV TX vaccine: available market ($000s) to 2030 (low scenario)
HSV TX vaccine: available market ($000s) to 2030 (base scenario)
HSV TX vaccine: available market ($000s) to 2030 (high scenario)
HSV TX vaccine: available market ($000s) to 2030 by country (base scenario)
HSV therapeutic vaccines: commercial model assumptions
Current management of genital herpes
The role of HSV TX vaccines
HSV TX vaccine target populations (scenario definition)
HSV TX vaccine: target product profile(s)
Model assumptions: populations/penetration rates/pricing/launch sequence
Markets included in model
Commercial model assumptions per TPP (LO/BASE/HI)
HSV TX vaccine segment analysis
Contribution of HSV-1 and HSV-2 to commercial value
HSV therapeutic vaccines: R&D pipeline
Competitor landscape: overview
HSV TX vaccine pipeline
Agenus
Preclinical programs
HSV therapeutic vaccines: Review on latest epidemiology
HSV-1/HSV-2: overview
HSV surveillance
Epidemiology: UK
Epidemiology: US
Epidemiology: other markets
HSV-1 and HSV-2 seroprevalence studies
Role of HSV-1 as a cause of genital herpes
Clinical reactivation of HSV-1 and HSV-2
Methodology: Calculating TX vaccine target populations
Bibliography
About VacZine Analytics
Disclaimer
PAGES: 66 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Title sheet
Scenario definition
Chart – value
Chart – volume
Volume summary
Value summary (High price)
Value summary (Base price)
Value summary (Low price)
Country worksheets ?
US
Canada
UK
France
Spain
Italy
Germany
Other EU
Japan
Australia
Sources
Herpes database (UK)
Herpes database (US)
Diagnoses rates
US NDTI diagnoses
UK HPA diagnoses
UK HPA by age
US HSV-2 seroprevalence
Back page
WORKSHEETS = 30

Drug and Medication in Europe

Portugal Pharmaceutical Sales, Us$bn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales, Eurbn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales At Constant Exchange Rate, Us$bn

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales, Us$ Per Capita

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe

Portugal Pharmaceutical Sales, % Of Gdp

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Infarmed, Association of European Self-Medication Industry (AESGP), European Federation of Pharmaceu

• Industries : Drug and Medication
• Countries : Portugal, Europe